5 Best Low Price Stocks To Watch For 2014

The Seaway pipeline, the joint venture between�Enterprise Products Partners (NYSE: EPD  ) and Enbridge (NYSE: ENB  ) , has taken on a life of its own, as speculators are trying to gain access to the last bit of capacity to sell the space on a secondary market. In this video, Fool.com contributor Aimee Duffy explains what is going on and why this pipeline matters so much to oil producers and investors alike.

The growing production of natural gas from hydraulic fracturing and horizontal drilling is flooding the North American market and resulting in record-low prices for natural gas. Enterprise Products Partners, with its superior integrated asset base, can profit from the massive bottlenecks in takeaway capacity by taking on large-scale projects. To help investors decide whether Enterprise Products Partners is a buy or a sell today, click here now to check out The Motley Fool's brand-new premium research report on the company.

10 Best Dividend Stocks For 2015: Cannabis Science Inc (CBIS)

Cannabis Science, Inc., incorporated on May 4, 2007, is a development-stage company. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treats disease and the symptoms of disease, as well as for general health maintenance. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).

The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.

Advisors' Opinion:

• [By Bryan Murphy]

  There's no denying it. Marijuana stocks like Cannabis Science Inc. (OTCMKTS:CBIS), Growlife Inc. (OTCBB:PHOT), and Medical Marijuana Inc. (OTCMKTS:MJNA) have gotten their second wind (and some would argue their third wind) over the past few days, doling out big gains in a very short period of time. MJNA is up 88% over the past four trading days, counting today. PHOT has popped 44% during that timeframe. CBIS has advanced 91% in just six days. It's everything a devoted shareholder of any of these companies could hope for, and more.

• [By Bryan Murphy]

  The last few days have been nothing less than incredible for stocks like Cannabis Science Inc. (OTCMKTS:CBIS), Medbox Inc. (OTCMKTS:MDBX), Growlife Inc. (OTCBB:PHOT), and Medical Marijuana Inc. (OTCMKTS:MJNA). MJNA shares have jumped 90% since last Friday. PHOT is up 51% for the same timeframe. CBIS has grown 150%, while MDBX is up 112%. The reason? It's largely the legalization of recreational marijuana in Colorado - a law that went into effect as of January 1st. The legalization of medical marijuana in Illinois on the same day didn't hurt either. And truth be told, the event-based rally from the likes of Medbox and Cannabis Science makes basic sense - it's a landmark shift in the way this country views and treats marijuana. On the flipside, before wading any deeper into stocks like Medical Marijuana or Growlife, current and would-be owners might want to take a step back and look at the bigger picture.

• [By John Udovich]

  Although its summer, there has been a steady stream of good news about medical marijuana even though important small cap marijuana stocks�Medical Marijuana Inc (OTCMKTS: MJNA) and Cannabis Science Inc (OTCMKTS: CBIS) have been fairly quietly lately while Growlife Inc (OTCBB: PHOT), a more indirect play on the spread of legalized marijuana, has produced�some news for investors:

5 Best Low Price Stocks To Watch For 2014: The Travelers Companies Inc.(TRV)

The Travelers Companies, Inc., through its subsidiaries, provides various commercial and personal property and casualty insurance products and services to businesses, government units, associations, and individuals primarily in the United States. The company operates in three segments: Business Insurance; Financial, Professional, and International Insurance; and Personal Insurance. The Business Insurance segment offers property and casualty products and services, such as commercial multi-peril, property, general liability, commercial auto, and workers? compensation insurance. It operates in six groups: Select Accounts, which serves small businesses; Commercial Accounts that serves mid-sized businesses; National Accounts, which serves large companies; Industry-Focused Underwriting that serves targeted industries; Target Risk Underwriting, which serves commercial businesses requiring specialized product underwriting, claims handling, and risk management services; and Special ized Distribution that offers products to customers through licensed wholesale, general, and program agents. The Financial, Professional, and International Insurance segment provides surety and financial liability coverage, which uses a credit-based underwriting process; and property and casualty products primarily in the United States., the United Kingdom, Ireland, and Canada. The Personal Insurance segment offers property and casualty insurance covering personal risks, primarily automobile and homeowners insurance to individuals. It distributes its products through independent agents, sponsoring organizations, joint marketing arrangements with other insurers, and direct marketing. The company was founded in 1853 and is based in New York, New York.

Advisors' Opinion:

• [By Dan Carroll]

  Not all stocks are up today, despite the surge. Travelers (NYSE: TRV  ) just can't find its footing. The stock has lost about 0.6% today, although Travelers has been as good a bet as any on the Dow over the past year: In that time, the stock has gained more than 47%. CEO Jay Fishman pointed out how falling bond yields have pressured the company's investments, pushing it to raise insurance coverage rates for some customers. It's not the end of the world for the company, but the sluggish economic rebound means that yields will likely remain depressed for some time. If another big disaster like last year's Hurricane Sandy comes around, Travelers could be in trouble.

• [By Matt Thalman]

  And finally, just as insurance investors seemed to have overcome the negative pull of superstorm Sandy, the Midwest was hit with a tornado that devastated suburbs of Oklahoma City. The tornado is probably the reason shares of Travelers (NYSE: TRV  ) fel 3.35% this past week, making the company the second worst performing Dow component during the past five trading sessions. But while this storm will probably weigh on Travelers' bottom line, as we saw with Sandy and other storms, the company plans for these types of events and will end up probably performing better than most expect. Anyone investing in insurance companies should fully understand that these events will happen, and when they do, not to panic-sell, but hold firm and wait for better days.

• [By WALLSTCHEATSHEET]

  Travelers provides valuable insurance products and services to an increasing number of consumers and companies. However, a recent earnings report has investors in the company feeling a bit disappointed. The stock has been on a modest rise over the last several months, but is now seeing a slight pullback. Over most of the last four quarters, investors in the company have had mixed feelings about the stock, though earnings and revenue figures have been rising. Relative to its peers and sector, Travelers has been an average year-to-date performer. WAIT AND SEE what Travelers does this coming quarter.

• [By Alex Planes]

  Perhaps it could. On June 8, 2009, the Dow's editors tapped Cisco (NASDAQ: CSCO  ) to replace the belly-up automaker, and also replaced floundering Citigroup (NYSE: C  ) with Travelers (NYSE: TRV  ) , its onetime subsidiary. When the change was announced, Dow Jones editor-in-chief Robert Thomson noted that Cisco was the right choice "because its communications and computer-networking products are vital to an economy and culture still adapting to the Information Age��-��ust as automobiles were essential to America in the 20th century." Citigroup's ouster was necessary as well, since its financial-crisis struggles had left the government with a substantial stake, and had left the bank in the midst of a "substantial restructuring."

5 Best Low Price Stocks To Watch For 2014: Yukon Gold Corporation Inc (YGDC)

Yukon Gold Corporation, Inc. (Yukon Gold) is an exploration-stage mining company. Yukon Gold is primarily engaged in the acquisition and exploration of mining properties. The Company seeks to explore, and if warranted and feasible, to develop mineralized material on the mineral claims located in the Mayo Mining District of Yukon, Canada. Yukon Gold holds these claims through its wholly owned subsidiary, Yukon Gold Corp. (YGC). On May 21, 2009, the Company, through YGC, sold its interest in the Mount Hinton Property to the Hinton Syndicate. YGC has 2% Net Smelter Royalty (NSR) on the Mount Hinton Property claims. Advisors' Opinion:

• [By Peter Graham]

  Last Friday, small cap energy or mining stocks Yukon Gold Corporation (OTCMKTS: YGDC) and Quantum Energy Inc (OTCMKTS: QEGY) surged 323.5% and 41.2%, respectively, while 1st NRG Corp (OTCMKTS: FNRC) sank 25%. However, it should also be mentioned that two of these small cap stocks have been the subject of paid promotions. With that in mind, will these small cap energy or mining stocks deliver some more Christmas cheer this week? Here is a closer look and a reality check:

5 Best Low Price Stocks To Watch For 2014: Inovio Pharmaceuticals Inc (INO)

Inovio Pharmaceuticals, Inc., incorporated on June 29, 1983, is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV). The Company's electroporation delivery technology uses brief, controlled electrical pulses to increase cellular uptake of the vaccine. Its clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV) and HIV vaccines. It is advancing preclinical research and clinical development for a universal seasonal/pandemic influenza vaccine, as well as preclinical work for other products, including malaria and prostate cancer vaccines. Its partners and collaborators include University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (PATH/MVI), National Institute of Allergy and Infectious Diseases (NIAID), Merck, ChronTech, University of Southampton, United States Military HIV Research Program (USMHRP), the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and HIV Vaccines Trial Network (HVTN). As of December 31, 2011 it owned 16.1% interest in VGX Int��.

Inovio�� Solution

The Company�� synthetic vaccine platform consists of its SynCon vaccine design process and electroporation delivery technology. It has developed a preclinical and clinical stage pipeline of vaccines. The Company�� synthetic vaccines are designed to prevent a disease (prophylactic vaccines) or treat an existing disease (therapeutic vaccines). Its synthetic vaccine consists of a deoxyribonucleic acid (DNA) plasmid encoding a selected antigen! (s), which is introduced into cells of humans or animals with the purpose of evoking an immune response to the encoded antigen. The Company�� synthetic vaccines are designed to generate specific antibody and/or T-cell responses.

The Company�� SynCon technology provides processes that employ bioinformatics, which combine extensive genetic data and sophisticated algorithms. Its design process uses the genetic make-up of a common antigen(s) from multiple strains of a virus within a viral sub-type or taxonomic group (family) of pathogens, such as HIV, hepatitis C virus (HCV), human papillomavirus (HPV), influenza and other diseases to synthetically create a new antigen for the desired pathogen target that does not exist in nature. Its synthetic vaccine candidates are being delivered into cells of the body using its electroporation (EP) DNA delivery technology.

Cancer Synthetic Vaccines

The Company has two broad types of cancer vaccines: preventive (or prophylactic) vaccines, which are intended to prevent cancer from developing in healthy people, and treatment (or therapeutic) vaccines, which are intended to treat an existing cancer by strengthening the body�� natural defenses against the cancer. Two types of cancer preventive vaccines are available in the United States. The United States Food and Drug Administration (the FDA) has approved two vaccines, Gardasil and Cervarix that protect against infection by the two types of HPV-types 16 and 18-that cause approximately 70% of all cases of cervical cancer worldwide. In addition, Gardasil protects against infection by two additional HPV types, 6 and 11, which are responsible for about 90% of all cases of genital warts in males and females but do not cause cervical cancer.

Cervarix manufactured by GlaxoSmithKline, is composed of virus-like particles (VLPs) made with proteins from HPV types 16 and 18. Cervarix is approved for use in females��ages 10 to 25 for the prevention of cervical cancer caused by! HPV type! s 16 and 18. Gardasil manufactured by Merck, is approved for use in females for the prevention of cervical cancer, and some vulvar and vaginal cancers, caused by HPV types 16 and 18 and for use in males and females for the prevention of genital warts caused by HPV types 6 and 11. The vaccine is approved for these uses in females and males ages 9 to 26. The FDA has also approved a cancer preventive vaccine that protects against hepatitis B virus (HBV) infection.

Inovio�� VGX-3100 is designed to raise immune responses against the E6 and E7 genes of HPV types 16 and 18 that are present in both pre-cancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into cancerous cells. In March 2011, it initiated a randomized, double-blind Phase II study of VGX-3100 delivered using the CELLECTRA intramuscular electroporation device in women with HPV Type 16 or 18 and diagnosed with, but not yet treated for, cervical intraepithelial neoplasia (CIN) 2/3. The study is designed to enroll 148 subjects. In January 2011, it announced the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of its SynCon vaccine for prostate cancer targeting two antigens, prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA).

In January 2011, the Company announced the regulatory approval of a Phase II clinical trial (WIN Trial) to treat leukemia utilizing its new ELGEN 1000 automated vaccine delivery device. The single dose level, Phase II study, called WT1 immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation. Cancer Vaccines encodes for hTERT, an antigen related to non-small cell lung, breast and prostate cancers. The vaccine is delivered using its electroporation delivery technology.

Infectious Disease Synthetic Vaccines

In Marc! h 2011, the Company announced the initiation of a follow-on open label, single dose Phase II clinical study in collaboration with ChronTech of the ChronVac-C HCV DNA vaccine delivered using its electroporation technology in treatment naive HCV infected individuals. Its HIV vaccines consist of candidates for HIV prevention, as well as therapy or treatment. PENNVAX-B is designed to target HIV clade B (most commonly found in the United States, North America, Australia and the European Union (EU). PENNVAX-G is designed to target HIV clades A, C and D, which are more commonly found in Asia, Africa, Russia and South America. This Phase I clinical study of PENNVAX-B (HVTN-080) vaccinated 48 healthy, HIV-negative volunteers to assess safety and levels of immune responses generated by Inovio�� PENNVAX-B vaccine delivered with its CELLECTRA electroporation device. PENNVAX-B is a SynCon vaccine that targets HIV gag, pol, and env proteins.

The Company�� VGX-3400X targets H5N1. The vaccine consists of three distinct DNA plasmids coded for a consensus hemagglutinin (HA) antigen derived from different H5N1 virus strains; a consensus neuraminidase (NA) antigen derived from different N1 sequences; and a consensus nucleoprotein (NP) fused to a small portion of the m2 protein (m2E) based on a broader cross-section of influenza viruses in addition to H5N1 and H1N1. Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season�� new strain(s). It is focused on developing DNA-based influenza vaccines able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.

Animal Health/Veterinary

VGX Animal Health, Inc. (VGX AH), a majority-owned subsidiary, has licensed LifeTide, a plasmid-based growth hormone releasing hormone (GHRH) technology for swine. LifeTide is one of onl! y four DN! A-based treatments approved for use in animals and is the only DNA-based agent delivered using electroporation that has been granted marketing approval (Australia). VGX AH is also developing a GHRH-based treatment for cancer and anemia in dogs and cats. It is developing a synthetic vaccine for foot-and-mouth disease (FMD) administered by its vaccine delivery technology. The FMD virus is one of the most infectious diseases affecting farm animals, including cattle, swine, sheep and goats, and is a serious threat to global food safety.

The Company competes with Crucell N.V, Sanofi-Aventis, Novartis, Inc., GlaxoSmithKline plc, Merck, Pfizer, AstraZeneca, Inc., Novartis, Inc., MedImmune and CSL.

Advisors' Opinion:

• [By Sean Williams]

  On the clinical data front, Alnylam Pharmaceuticals (NASDAQ: ALNY  ) and Inovio Pharmaceuticals (NYSEMKT: INO  ) both put investors in their happy place.

• [By George Budwell]

  Inovio Pharmaceuticals (NYSEMKT: INO  ) develops DNA-based vaccines and delivers them using a proprietary electroporation technique. Shares of Inovio have been a roller coaster all year long, and have certainly been the playground of day traders. Last week, Inovio shares lost more than 10% of their value on heavy volume, suggesting the stock may continue to experience downward pressure. This rapid move downward is surprising because the company recently signed a licensing deal with Roche (NASDAQOTH: RHHBY  ) to commercialize Inovio's multi-antigen DNA immunotherapies for prostate cancer and hepatitis B. As part of the deal, Inovio received $10 million upfront, and milestone payments could go as high as $412 million.